Bone biopsy in patients with osteoporosis

Current Osteoporosis Reports

Volumn 5, Issue 4, 2007, Pages 146-152

  Malluche, Hartmut H ^a   Mawad, Hanna ^b   Monier Faugere, Marie Claude ^b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; IBANDRONIC ACID; PARATHYROID HORMONE[1-34];

BONE BIOPSY; BONE MINERALIZATION; BONE REMODELING; BONE TURNOVER; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEMATOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFRARED SPECTROSCOPY; MEDICAL ASSESSMENT; MORPHOMETRICS; NERVE INJURY; OSSIFICATION; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PAIN; POSTMENOPAUSE; REVIEW; WOUND INFECTION;

EID: 38049014389     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-007-0009-x     Document Type: Review

References (33)

1. Meunier P, Courpron P, Edouard C, et al.: Physiological senile involution and pathological rarefaction of bone. Quantitative and comparative histological data. Clin Endocrinol Metab 1973, 2:239-256.
2. Dorr LD, Arnala I, Faugere MC, et al.: Five-year postoperative results of cemented femoral arthroplasty in patients with systemic bone disease. Clin Orthop Relat Res 1990, 259:114-121.
3. Dorr LD, Faugere MC, Mackel AM, et al.: Structural and cellular assessment of bone quality of proximal femur. Bone 1993, 14:231-242.
4. Malluche HH, Meyer W, Sherman D, et al.: Quantitative bone histology in 84 normal American subjects. Micromorphometric analysis and evaluation of variance in iliac bone. Calcif Tissue Int 1982, 34:449-455.
5. Malluche HH, Faugere MC: Atlas of Mineralized Bone Histology. New York: Karger; 1986.
6. Duncan H, Rao S, Parfitt AM: Complications of bone biopsy. In Bone Histomorphometry. Edited by Jee W, Parfitt AM. Paris: Societe Nouvelles de Publications Medicales et Dentaires; 1981:483-486
7. Johnson KA, Kelly PJ, Jowsey J: Percutaneous biopsy of the iliac crest. Clin Orthop Relat Res 1977, 123:34-36.
8. Parfitt A: Stereologic basis of bone histomorphometry; theory of quantitative microscopy and reconstruction of the third dimension. In Bone Histomorphometry: Techniques and Interpretation. Edited by Recker RR. Boca Raton, FL: CRC Press; 1983:53-87.
9. Meunier P: Bone histomorphometry. In Osteoporosis: Etiology, Diagnosis, and Management, edn 2. Edited by Riggs BL, Melton LJ III. Philadelphia: Lippincott-Raven; 1995:299-318.
10. Faugere MC, Friedler RM, Fanti P, et al.: Bone changes occurring early after cessation of ovarian function in beagle dogs: a histomorphometric study employing sequential biopsies. J Bone Miner Res 1990, 5:263-272.
11. Malluche HH, Faugere MC, Rush M, et al.: Osteoblastic insufficiency is responsible for maintenance of osteopenia after loss of ovarian function in experimental beagle dogs. Endocrinology 1986, 119:2649-2654.
12. Monier-Faugere MC, Friedler RM, Bauss F, et al.: A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 1993, 8:1345-1355.
13. Lips P, Courpron P, Meunier PJ: Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res 1978, 26:13-17.
14. Recker R, Lappe J, Davies KM, et al.: Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 2004, 19:1628-1633.
15. • Donovan MA, Dempster D, Zhou H, et al.: Low bone formation in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 2005, 90:3331-3336. This article describes the bone histologic abnormalities in premenopausal women with idiopathic osteoporosis, finding that women with idiopathic osteoporosis have lower bone formation rate and longer resorption period than normal controls.
16. Bone HG, Greenspan SL, McKeever C, et al.: Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000, 85:720-726.
17. McClung M, Clemmesen B, Daifotis A, et al.: Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998, 128:253-261.
18. Recker RR, Weinstein RS, Chesnut CH 3rd, et al.: Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 2004, 15:231-237.
19. •• Arlot M, Meunier PJ, Boivin G, et al: Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005, 20:1244-1253. This study compares the effects of 6 or 18 months' treatment with teriparatide or alendronate on bone, showing that teriparatide treatment increases bone formation and to a lesser degree bone resorption when compared with alendronate treatment.
20. •• Lindsay R, Zhou H, Cosman F, et al.: Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 2007, 22:495-502. This article investigates the mechanisms of the anabolic action of teriparatide on bone, finding that teriparatide stimulates bone formation at ongoing remodeling sites and increases osteoblast apoptosis, which may reflect enhanced turnover of the osteoblastic population.
21. McCabe JT, Bolendcr RP: Estimation of tissue mRNAs by in situ hybridization. J Histochem Cytochem 1993, 41:1777-1783.
22. Ikeda T, Nagai Y, Yamaguchi A, et al.: Age-related reduction in bone matrix protein mRNA expression in rat bone tissues: application of histomorphometry to in situ hybridization. Bone 1995, 16:17-23.
23. Ikeda T, Nomura S, Yamaguchi A, et al.: In situ hybridization of bone matrix proteins in undecalcified adult rat bone sections. J Histochem Cytochem 1992, 40:1079-1088.
24. Ikeda T, Yamaguchi A, Yokose S, et al.: Changes in biological activity of bone cells in ovariectomized rats revealed by in situ hybridization. J Bone Miner Res 1996, 11:780-788.
25. Weinreb M, Shinar D, Rodan GA: Different pattern of alkaline phosphatase, osteopontin, and osteocalcin expression in developing rat bone visualized by in situ hybridization. J Bone Miner Res 1990, 5:831-842.
26. Davideau JL, Papagerakis P, Hotton D, et al.: In situ investigation of vitamin D receptor, alkaline phosphatase, and osteocalcin gene expression in oro-facial mineralized tissues. Endocrinology 1996, 137:3577-3585.
27. Mee AP, Hoyland JA, Braidman IP, et al.: Demonstration of vitamin D receptor transcripts in actively resorbing osteoclasts in bone sections. Bone 1996, 18:295-299.
28. Dodds RA, Merry K, Littlewood A, et al.: Expression of mRNA for IL1 beta, IL6 and TGF beta 1 in developing human bone and cartilage. J Histochem Cytochem 1994, 42:733-744.
29. Langub MC Jr, Koszewski NJ, Turner HV, et al.: Bone resorption and mRNA expression of IL-6 and IL-6 receptor in patients with renal osteodystrophy. Kidney Int 1996, 50:515-520.
30. Boskey AL, DiCarlo E, Paschalis E, et al.: Comparison of mineral quality and quantity in iliac crest biopsies from high- and low-turnover osteoporosis: an FT-IR microspectroscopic investigation. Osteoporos Int 2005, 16:2031-2038. This article reports mineral quality in controls and osteoporotic patients with high or low bone turnover.
31. Porter D, Faugere M, Pienkowski D, et al.: Gender related differences in bone mineral quality. J Bone Miner Res 2007, In press.
32. Carter DR, Hayes WC: Bone compressive strength: the influence of density and strain rate. Science 1976, 194:1174-1176.
33. Wainwright S, Briggs W, Currey J, et al.: Mechanical Design in Organisms. New York: Halsted Press; 1976.